Skip to content

A study for the efficacy and safety of aerobic exercise in the treatment of chronic thromboembolic pulmonary hypertension

A study for the efficacy and safety of aerobic exercise in the treatment of chronic thromboembolic pulmonary hypertension

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031643
Enrollment
Unknown
Registered
2020-04-05
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic thromoboembolic pulmonary hypertension

Interventions

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Chronic thromboembolic pulmonary hypertension (CTEPH) patients

Exclusion criteria

Exclusion criteria: 1. Patients with absolute contraindications: (1) Acute myocardial infarction (within 2 days); (2) Uncontrolled unstable angina; (3) Uncontrolled arrhythmia leads to hemodynamic instability; (4) Acute endocarditis; (5) Symptomatic severe coarctation of the aorta; (6) Decompensated heart failure; (7) Acute pulmonary embolism, pulmonary infarction or deep vein thrombosis; (8) Acute myocarditis or pericarditis; (9) Acute aortic dissection; (10) Disabled people have potential safety hazards or can not fully complete the exercise test. 2. Patients with relative contraindications: (1) Stenosis of the left main coronary artery was known; (2) Moderate to severe aortic stenosis was associated with uncertain symptoms; (3) Uncontrolled ventricular tachycardia; (4) Acquired high or complete atrioventricular block; (5) Severe hypertrophic obstructive cardiomyopathy (high pressure difference in resting outflow tract); (6) Recent stroke or transient ischemic attack; (7) Those who are difficult to cooperate with; (8) Resting blood pressure > 200 / 110mmhg; (9) Uncorrected clinical problems such as severe anemia, electrolyte disorders, and hyperthyroidism. 3. WHO group 2 pH /WHO group 3 PH /WHO group 5 pH

Design outcomes

Primary

MeasureTime frame
peak VO2/kg;Proteomics, transcriptome;

Secondary

MeasureTime frame
6MWT;WHO FC;Cardiopulmonary exercise testing;Echocardiography;Stress echocardiography;Capography;Cardiac MRI;NT-proBNP;biochemistry;

Countries

China

Contacts

Public ContactJiang Rong

Shanghai Pulmonary Hospital

listening39@163.com+86 13795493921

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026